Together, we are making a difference

OPADE’s objective is to identify key biomarkers that support the decision-making process of the healthcare providers through the development and commercialisation of an AI (artificial intelligence) / ML (machine learning) -predictive tool. The project focuses on the gut–brain-axis which plays a major role in MDD. 

​

In the heart of innovation and healthcare technology, the MiWear project emerges as a beacon of transformative change, funded by the European Innovation Council. This ambitious initiative, led by QUANTUNE TECHNOLOGIES GmbH alongside a consortium of European experts, is pioneering the development of a wearable device that promises to redefine the way Metabolic Syndrome and its related conditions are monitored.

This COST Action aims to bridge the gap between groundbreaking scientific research and improved clinical care for brain cancer patients. Key objectives include: establishing a pan-European, multidisciplinary network to advance brain cancer research; fostering education in neuroscience, neuroimaging, genetics, molecular biology, and big data for better diagnosis, prognosis, and treatment; and creating an integrated European brain cancer database and biobank platform to support both research and clinical efforts.